What is Brief History of Glaukos Company?

What is Glaukos Corporation?

Glaukos Corporation began in 1998 in Laguna Hills, California, with a goal to treat chronic eye disease in new ways. Its history turned notable in 2012 when iStent helped show glaucoma surgery could be less invasive. For more context, see Glaukos Balanced Scorecard.

Glaukos Corporation later expanded from glaucoma into corneal health and retinal disease. That shift made its brief history useful because it shows how a medical tech firm can build trust through clinical proof.

Glaukos Corporation was founded in 1998 in Laguna Hills, California by Thomas W. Burns to address glaucoma care with less invasive treatment options. The brief history of Glaukos Corporation starts with a clear goal: reduce intraocular pressure without relying only on lifelong drops or more disruptive surgery.

Founding Story of Glaukos Corporation

The Glaukos founder built the Glaukos medical device company around a narrow but hard problem in eye care. The first business model focused on a device platform that could change glaucoma treatment, and the Owners & Shareholders of Glaukos page traces how that early vision shaped the Glaukos Company history.

• Founded in 1998 in Laguna Hills, California
• Founded by Thomas W. Burns
• Targeted glaucoma care and intraocular pressure
• Built around the iStent trabecular micro-bypass stent

In the Glaukos company overview, the original name stayed close to glaucoma, which signaled a direct focus instead of a broad medtech pitch. That helped define the Glaukos company background and Glaukos business model history from the start, with the company aiming to create a new surgical category in MIGS, or minimally invasive glaucoma surgery.

Early perception was cautious. Surgeons saw the clinical logic, but the market was still new, reimbursement was forming, and the company had to educate users while funding long regulatory cycles, so the Glaukos growth timeline began as a high-risk category build rather than a fast sales story.

That is why the Glaukos Corporation founding story matters in any look at the Glaukos glaucoma treatment company. The Glaukos first product launch, centered on the iStent concept, showed how Glaukos innovation in eye care started with one device idea and a long path from lab need to market use.

Glaukos SWOT Analysis

• Organized to Save Time on Analysis
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Glaukos Corporation began as a small Glaukos medical device company focused on micro-invasive glaucoma surgery and grew into a broader eye-care platform. The brief history of Glaukos is marked by the iStent launch, a Glaukos IPO history milestone, the 2019 Avedro deal, and the 2023 iDose TR approval, each step widening its reach in glaucoma and corneal care.

From iStent to a repeatable platform

The early Glaukos Company history started with one idea: use a tiny implant to reduce eye pressure in glaucoma. The Glaukos founder, Thomas Burns, helped build a model around surgeon adoption, clinical evidence, and product iteration, which shaped the Glaukos business model history.

That approach made the first product launch more than a single device event. It created a platform the Growth Strategy of Glaukos could extend across next-generation MIGS products, supporting the Glaukos growth timeline and early international visibility.

How Glaukos became a public company

Glaukos became a public company in 2015, after filing for an IPO in 2014 and listing on the New York Stock Exchange in June 2015. The offering increased capital for R&D and commercialization, and it marked a shift from startup-style development to a scaled ophthalmology business.

At that point, the Glaukos company overview was still centered on glaucoma, but the company had stronger reach, deeper clinical data, and more room to expand. That is a key part of the Glaukos Corporation history and Glaukos company milestones.

2019 acquisition history and corneal expansion

The biggest change in Glaukos acquisition history came in 2019, when Glaukos acquired Avedro for about USD 350 million. That move brought corneal cross-linking into the portfolio through the KXL platform and Photrexa-based therapy, expanding the Glaukos glaucoma treatment company into corneal health at scale.

This was the moment the brief history of Glaukos Corporation became broader than a single device category. It also changed the Glaukos company background from MIGS-only innovation to a multi-therapy eye-care platform.

2023 drug-device platform shift

In 2023, FDA approval of iDose TR pushed Glaukos further into sustained-release medication delivery. That approval showed the brand was no longer only a MIGS story; it was becoming a drug-device platform built to address chronic eye disease through surgery, corneal therapy, and drug delivery.

This stage is central to Glaukos innovation in eye care and the modern Glaukos Corporation founding story as it evolved. It also links back to the Glaukos headquarters history and growth from a niche device maker to a broader ophthalmology franchise.

Glaukos Ansoff Matrix

• Structured to Support Better Decisions
• Effortlessly Communicate Your Business Strategy
• Investor-Ready Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Glaukos Corporation history is shaped by early approval, category creation, and the harder work of keeping momentum. The Brief history of Glaukos shows how the Glaukos medical device company moved from first-mover status in glaucoma care to a broader eye-care platform, while investors kept watching execution, adoption, and scale.

Glaukos innovation in eye care has centered on devices and delivery systems that try to lower pressure without the same burden as older surgery. The Glaukos first product launch built a platform story, and the later pipeline helped answer the question of how Glaukos became a public company that could still grow after its first hit.

First-Mover MIGS Position

iStent approval in 2012 gave Glaukos Corporation early credibility in MIGS and made the Glaukos company milestones easier to recognize in the market.

Platform Expansion

The Avedro deal in 2019 showed the Glaukos company overview was broader than a single glaucoma device and helped reshape Glaukos headquarters history into a multi-platform story.

Drug Delivery Step-Up

iDose TR approval in 2023 added a sustained-release therapy angle and strengthened Glaukos innovation in eye care.

Public Market Discipline

Glaukos IPO history matters because public investors reward new products only when they also see repeatable sales, margin gains, and tighter execution.

Category Creation

By helping define MIGS, Glaukos Corporation built reputation value that went beyond any one launch and supported the Glaukos Corporation history narrative.

Strategic Discipline

The shift from a single product story to a broader portfolio helped answer who founded Glaukos Company by showing that founder-led innovation could turn into a scalable medtech model.

The main challenge in the Glaukos Company background has been adoption speed. Surgeons need training, reimbursement can lag, and the company has had to keep funding R&D and sales before economics fully scale.

Another challenge is reputation pressure from execution, not invention. Glaukos Corporation was respected for being early, but the market still judges it on durable growth, operating leverage, and whether each launch can become a real revenue base.

Slow Adoption Curves

New glaucoma procedures often take time to spread across practices. That has meant Glaukos Corporation had to wait for surgeon comfort and patient flow to catch up.

Reimbursement Friction

Payment rules can slow use even when doctors like the product. This has been a recurring pressure point in the Glaukos growth timeline.

Heavy Commercial Spend

Sales force buildout and training costs stay high before scale arrives. That has kept margins under pressure at key stages of the Glaukos business model history.

One-Trick Risk

Investors once saw Glaukos Corporation mostly as a MIGS name. iDose TR helped reduce that risk, but proof of breadth still matters.

Execution Over Hype

The market values Glaukos invention, but it wants repeatable results too. That tension sits at the center of the brief history of Glaukos Corporation.

Strategy Watch

For a fuller view of positioning and market messaging, see Marketing Strategy of Glaukos.

Glaukos Balanced Scorecard

• Clean, Modern, and Easy to Present
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Glaukos Corporation history shows a clear pattern: the Glaukos medical device company grows by pairing new eye-care science with regulatory wins and surgeon adoption. From its 1998 founding in Laguna Hills to iStent, the 2012 FDA approval, the 2014 IPO, the 2019 Avedro deal, and the 2023 iDose TR approval, the Glaukos growth timeline shows steady expansion across chronic eye disease.

What the history says about the brand

The brief history of Glaukos shows a brand built on clinical novelty and proof, not hype. That matters because surgeons tend to trust products that solve a real problem and clear regulatory review.

Why the 2012 and 2023 approvals matter

The 2012 iStent approval and the 2023 iDose TR approval anchor the Glaukos company milestones. They show the Glaukos glaucoma treatment company can move from device-led care into drug-device care.

Where growth may come from next

In 2025, the key test is execution across MIGS, corneal care, and pharmaceutical ophthalmology. The Glaukos company overview suggests more room to grow, but only if clinical results, surgeon trust, and commercial follow-through stay aligned.

How investors may read the timeline

The Competitors Landscape of Glaukos helps frame the competitive side of the story. The Glaukos IPO history and later Avedro deal suggest a company that uses capital and M and A to widen its reach, not just defend one product line.

Glaukos VRIO Analysis

• Designed for Fast Business Analysis
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔